59 results
8-K
EX-1.1
TPST
Tempest Therapeutics, Inc.
20 Jun 24
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
8:13am
as defined by the Public Company Accounting Oversight Board (the “PCAOB”) whose registration has not been suspended or revoked and who has not requested
8-K
EX-10.1
ua3uchzn
2 May 22
Tempest Announces Private Placement Financing of $15 Million
8:02am
PRE 14A
lvpxm
22 Apr 22
Preliminary proxy
4:01pm
8-K
EX-1.1
qrvhfujemwq8gsb
23 Jul 21
Other Events
5:20pm
8-K
EX-99.1
2zg1nhspajimwdd7n
16 Jul 21
Other Events
4:31pm
8-K
EX-99.4
6npznnltn r4y2ju0p7h
16 Jul 21
Other Events
4:31pm
424B3
jg2ft 8uc7
11 May 21
Prospectus supplement
5:19pm
8-K
EX-2.1
1wqd002unvmme3f5
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
1gour5otrqn
29 Mar 21
Business combination disclosure
7:27am